Roquefort Therapeutics (LON:COIL) Stock Price Down 5% – Should You Sell?

Roquefort Therapeutics plc (LON:COIL)’s share price traded down 5% on Wednesday . The stock traded as low as GBX 9.50 and last traded at GBX 9.50. Approximately 310,553 shares changed hands during trading, an increase of 18% from the average daily volume of 262,156 shares. The stock had previously closed at GBX 10.

Roquefort Therapeutics Price Performance

The stock has a market cap of £40.55 million, a PE ratio of -0.43 and a beta of 0.05. The business has a fifty day simple moving average of GBX 10.25 and a two-hundred day simple moving average of GBX 10.30. The company has a current ratio of 0.63, a quick ratio of 3.07 and a debt-to-equity ratio of 8.18.

Roquefort Therapeutics (LON:COIL) last released its earnings results on Wednesday, May 6th. The company reported GBX (2.19) EPS for the quarter. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative return on equity of 18.71%.

About Roquefort Therapeutics

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.